<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11863089</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.572</article-id><article-id pub-id-type="other">EPP0421</article-id><article-id pub-id-type="pii">S0924933824005728</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Exploring Associations between Grey Matter Volume and Clinical High-Risk for Psychosis: A Transdiagnostic Study Utilizing the NAPLS-2 Risk Calculator in the PRONIA Cohort</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Neuner</surname><given-names>L.-M.</given-names></name><xref rid="aff1288" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor0433" ref-type="corresp">
<sup>*</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hahn</surname><given-names>L.</given-names></name><xref rid="aff1288" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kambeitz</surname><given-names>J.</given-names></name><xref rid="aff1289" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Salokangas</surname><given-names>R. K.</given-names></name><xref rid="aff1290" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Hietala</surname><given-names>J.</given-names></name><xref rid="aff1290" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bertolino</surname><given-names>A.</given-names></name><xref rid="aff1291" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Borgwardt</surname><given-names>S.</given-names></name><xref rid="aff1292" ref-type="aff">
<sup>5</sup>
</xref><xref rid="aff1293" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Brambilla</surname><given-names>P.</given-names></name><xref rid="aff1294" ref-type="aff">
<sup>7</sup>
</xref><xref rid="aff1295" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Upthegrove</surname><given-names>R.</given-names></name><xref rid="aff1296" ref-type="aff">
<sup>9</sup>
</xref><xref rid="aff1297" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Wood</surname><given-names>S. J.</given-names></name><xref rid="aff1298" ref-type="aff">
<sup>11</sup>
</xref><xref rid="aff1299" ref-type="aff">
<sup>12</sup>
</xref><xref rid="aff1300" ref-type="aff">
<sup>13</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lencer</surname><given-names>R.</given-names></name><xref rid="aff1292" ref-type="aff">
<sup>5</sup>
</xref><xref rid="aff1301" ref-type="aff">
<sup>14</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Meisenzahl</surname><given-names>E.</given-names></name><xref rid="aff1302" ref-type="aff">
<sup>15</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Falkai</surname><given-names>P.</given-names></name><xref rid="aff1288" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff1303" ref-type="aff">
<sup>16</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Cannon</surname><given-names>T. D.</given-names></name><xref rid="aff1304" ref-type="aff">
<sup>17</sup>
</xref><xref rid="aff1305" ref-type="aff">
<sup>18</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Koutsouleris</surname><given-names>N.</given-names></name><xref rid="aff1288" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff1303" ref-type="aff">
<sup>16</sup>
</xref><xref rid="aff1306" ref-type="aff">
<sup>19</sup>
</xref></contrib></contrib-group><aff id="aff1288">
<sup>1</sup>Department of Psychiatry and Psychotherapy, <institution>LMU University Hospital, Ludwig-Maximilians-Universit&#x000e4;t</institution>, <city>Munich</city>
</aff><aff id="aff1289">
<sup>2</sup>Department of Psychiatry and Psychotherapy, <institution>University of Cologne</institution>, <city>Cologne</city>, <country>Germany</country>
</aff><aff id="aff1290">
<sup>3</sup>Department of Psychiatry, <institution>University of Turku</institution>, <city>Turku</city>, <country>Finland</country>
</aff><aff id="aff1291">
<sup>4</sup>Department of Basic Medical Science, Neuroscience and Sense Organs, <institution>University of Bari Aldo Moro</institution>, <city>Bari</city>, <country>Italy</country>
</aff><aff id="aff1292">
<sup>5</sup>Department of Psychiatry and Psychotherapy, <institution>University of L&#x000fc;beck</institution>, <city>L&#x000fc;beck</city>, <country>Germany</country>
</aff><aff id="aff1293">
<sup>6</sup>Department of Psychiatry (Psychiatric University Hospital, UPK), <institution>University of Basel</institution>, <city>Basel</city>, <country>Switzerland</country>
</aff><aff id="aff1294">
<sup>7</sup>Department of Neurosciences and Mental Health, <institution>Fondazione IRCCS Ca&#x02019; Granda Ospedale Maggiore Policlinico</institution>
</aff><aff id="aff1295">
<sup>8</sup>Department of Pathophysiology and Transplantation, <institution>University of Milan</institution>, <city>Milan</city>, <country>Italy</country>
</aff><aff id="aff1296">
<sup>9</sup>Institute of Mental Health, <institution>University of Birmingham</institution>
</aff><aff id="aff1297">
<sup>10</sup><institution>Early Intervention Service, Birmingham Women&#x02019;s and Children&#x02019;s NHS Foundation Trust</institution>
</aff><aff id="aff1298">
<sup>11</sup>School of Psychology, <institution>University of Birmingham</institution>, <city>Birmingham</city>, <country>United Kingdom</country>
</aff><aff id="aff1299">
<sup>12</sup>Centre for Youth Mental Health, <institution>University of Melbourne</institution>
</aff><aff id="aff1300">
<sup>13</sup><institution>Orygen</institution>, <city>Melbourne</city>, <country>
Australia</country>
</aff><aff id="aff1301">
<sup>14</sup><institution>Institute for Translational Psychiatry, University M&#x000fc;nster</institution>, <city>M&#x000fc;nster</city>
</aff><aff id="aff1302">
<sup>15</sup>Department of Psychiatry and Psychotherapy, Medical Faculty, <institution>Heinrich Heine University</institution>, <city>D&#x000fc;sseldorf</city>
</aff><aff id="aff1303">
<sup>16</sup><institution>Max-Planck Institute of Psychiatry</institution>, <city>Munich</city>, <country>Germany</country>
</aff><aff id="aff1304">
<sup>17</sup>Department of Psychiatry</aff><aff id="aff1305">
<sup>18</sup>Department of Psychology, <institution>Yale University</institution>, <city>New Haven</city>, <state>Connecticut</state>, <country>United States</country>
</aff><aff id="aff1306">
<sup>19</sup>Institute of Psychiatry, Psychology And Neurosciences, <institution>King&#x02019;s College London</institution>, <city>
London</city>, <country>United Kingdom</country>
</aff><author-notes><corresp id="cor0433">
<label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="547">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S271</fpage><lpage>S272</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824005728a.pdf"/><abstract><sec id="sec2599"><title>Introduction</title><p>
The clinical high-risk state for psychosis (CHR) is associated with alterations in grey matter volume (GMV) in various regions such as the hippocampus (Vissink <italic toggle="yes">et al.</italic> BP:GOS 2022; 2(2) 147-152). Within the scope of the North American Prodrome Longitudinal Study (NAPLS-2; Cannon <italic toggle="yes">et al.</italic> AM J Psychiatry 2016; 173(10), 980-988), a publicly available risk calculator based on clinical variables was developed to assess the likelihood of individuals to transition to psychosis within a 2-year period.</p></sec><sec id="sec2600"><title>Objectives</title><p>
In the current study, we aim to examine the association between GMV and NAPLS-2 risk scores calculated for individuals with CHR and recent-onset depression (ROD), taking a transdiagnostic approach on the transition to psychosis.</p></sec><sec id="sec2601"><title>Methods</title><p>
The sample consisted of 315 CHR (<italic toggle="yes">M</italic> = 23.85, <italic toggle="yes">SD</italic> = &#x000b1; 5.64; female: 164) and 295 ROD (<italic toggle="yes">M</italic> = 25.11, <italic toggle="yes">SD</italic> = &#x000b1; 6.21; female: 144) patients from the multi-site Personalised Prognostic Tools for Early Psychosis Management (PRONIA) Study (Koutsouleris <italic toggle="yes">et al</italic>. JAMA Psychiatry 2018; 57(11), 1156-1172). Risk scores were calculated using the six clinical and neurocognitive variables included in the NAPLS-2 risk calculator that were significant for predicting psychosis. Further, we derived smoothed GMV maps from T1-weighted structural magnetic resonance imaging using a full width at half maximum kernel size of 8 mm. We employed a multiple regression design in SPM12 to examine associations between risk scores and GMV. On the whole-brain level, we calculated permutation-based threshold-free cluster enhancement (TFCE) contrasts using the TFCE toolbox. Additionally, we calculated t-contrasts within a region-of-interest (ROI) analysis encompassing the hippocampus. All results were thresholded at p &#x0003c; 0.05 with family wise error correction to address multiple comparisons.</p></sec><sec id="sec2602"><title>Results</title><p>Our analysis revealed that linear GMV increases in the right middle and superior frontal gyrus (k<sub>E</sub>= 2726 voxels) were significantly associated with higher risk for psychosis transition within two years (see figure 1, highlighted in blue). In the ROI analysis, we found a significant negative linear association between GMV decreases in the left hippocampus (k<sub>E</sub> = 353 voxels) and higher risk for psychosis transition (see figure 1, highlighted in red).</p><p>
<bold>Image:</bold></p><p>
<fig position="float" id="fig0062"><graphic xlink:href="S0924933824005728-FIG0062" position="anchor"/></fig>
</p></sec><sec id="sec2603"><title>Conclusions</title><p>GMV reductions in the hippocampus have frequently been observed in CHR and psychosis patients (Vissink <italic toggle="yes">et al.</italic> BP:GOS 2022; 2(2) 147-152), therefore our results further highlight the crucial role of this region in the progression of the disease. There is limited evidence on GMV increases in CHR patients. However, the GMV increase we found in the frontal pole may reflect compensatory mechanisms of the brain in the development of psychosis. In addition, we were able to provide biological validation of the NAPLS-2 risk calculator and its assessment of risk for transition to psychosis.</p></sec><sec id="sec2604"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="2"/></counts></article-meta></front></article>